394 related articles for article (PubMed ID: 28501075)
1. Gadolinium Retention and Toxicity-An Update.
Ramalho M; Ramalho J; Burke LM; Semelka RC
Adv Chronic Kidney Dis; 2017 May; 24(3):138-146. PubMed ID: 28501075
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium toxicity and treatment.
Ramalho J; Ramalho M; Jay M; Burke LM; Semelka RC
Magn Reson Imaging; 2016 Dec; 34(10):1394-1398. PubMed ID: 27693607
[TBL] [Abstract][Full Text] [Related]
3. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms.
Rogosnitzky M; Branch S
Biometals; 2016 Jun; 29(3):365-76. PubMed ID: 27053146
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium Deposition and Chronic Toxicity.
Ramalho J; Ramalho M
Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):765-778. PubMed ID: 28964466
[TBL] [Abstract][Full Text] [Related]
6. Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?
Layne KA; Wood DM; Dargan PI
Clin Toxicol (Phila); 2020 Mar; 58(3):151-160. PubMed ID: 31663374
[No Abstract] [Full Text] [Related]
7. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
Pedersen M
J Magn Reson Imaging; 2007 May; 25(5):881-3. PubMed ID: 17457808
[No Abstract] [Full Text] [Related]
8. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.
Mathur M; Jones JR; Weinreb JC
Radiographics; 2020; 40(1):153-162. PubMed ID: 31809230
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium tissue deposition in brain and bone.
Murata N; Murata K; Gonzalez-Cuyar LF; Maravilla KR
Magn Reson Imaging; 2016 Dec; 34(10):1359-1365. PubMed ID: 27720805
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
Layne KA; Dargan PI; Archer JRH; Wood DM
Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium-Induced Fibrosis.
Todd DJ; Kay J
Annu Rev Med; 2016; 67():273-91. PubMed ID: 26768242
[TBL] [Abstract][Full Text] [Related]
12. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus.
Runge VM
Invest Radiol; 2016 May; 51(5):273-9. PubMed ID: 26945278
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.
Ramalho J; Semelka RC; Ramalho M; Nunes RH; AlObaidy M; Castillo M
AJNR Am J Neuroradiol; 2016 Jul; 37(7):1192-8. PubMed ID: 26659341
[TBL] [Abstract][Full Text] [Related]
14. Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.
Bhave G; Lewis JB; Chang SS
J Urol; 2008 Sep; 180(3):830-5; discussion 835. PubMed ID: 18635232
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis: a report of 29 cases.
Shabana WM; Cohan RH; Ellis JH; Hussain HK; Francis IR; Su LD; Mukherji SK; Swartz RD
AJR Am J Roentgenol; 2008 Mar; 190(3):736-41. PubMed ID: 18287446
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium deposition in the brain.
Kanda T; Nakai Y; Oba H; Toyoda K; Kitajima K; Furui S
Magn Reson Imaging; 2016 Dec; 34(10):1346-1350. PubMed ID: 27613998
[TBL] [Abstract][Full Text] [Related]
17. Safety of Contrast Material Use in Children.
Soares BP; Lequin MH; Huisman TAGM
Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):779-785. PubMed ID: 28964467
[TBL] [Abstract][Full Text] [Related]
18. On the potential causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis.
Partain CL
J Magn Reson Imaging; 2007 May; 25(5):879-80. PubMed ID: 17457806
[No Abstract] [Full Text] [Related]
19. Gadolinium retention in the body: what we know and what we can do.
Tedeschi E; Caranci F; Giordano F; Angelini V; Cocozza S; Brunetti A
Radiol Med; 2017 Aug; 122(8):589-600. PubMed ID: 28361260
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
